



**INDO US**  
**BIO-TECH LIMITED**  
 (AN ISO CERTIFIED COMPANY)  
 CIN LO1122GJ2004PLC043550



## PRIVATE PLACEMENT OFFER LETTER

[Pursuant to section 42 of Companies Act, 2013 and rule 14(1) of Companies (Prospectus and Allotment of Securities) Rules, 2014]

### 1. GENERAL INFORMATION

a.	Name, address, website and other contact details of the company indicating both registered office and corporate office	<p>INDO US BIO-TECH LIMITED</p> <p>Registered Address: 309, Shanti Mall, Satadhar Char Rasta Opp. Navrang Tower, Sola Road Ahmedabad 380061 Gujarat India</p> <p>Corporate Address: same as registered. Address</p> <p>Website: <a href="http://indousagriseeds.com">indousagriseeds.com</a></p> <p>E-Mail: <a href="mailto:indouscs@gmail.com">indouscs@gmail.com</a></p>
b.	Date of incorporation of the company	04/02/2004
c.	Business carried on by the company and its subsidiaries with the details of branches or units, if any	<p>To carry on business as manufacturers, stockiest, processors, formulators, buyers, sellers, Importers, exporters, growers, producers and dealers in all types and kinds of seed including hybrid seeds which are used in and for agriculture and allied activities and also buy , sell or produce bio-fertilizers and other fertilizers used in agriculture activities and also own, occupy, purchase, sell, deal in acquired ,hold,hire,possess,exchange,lease,licence,improve,grow,devlop,manager,control land and set up agriculture farms, farms houses, orchards, and to carry on the business as agriculturist,farmers,millers,gardeners,cullivators,planters,processes in connection with the agriculture and farming activities.</p>





**INDO US**  
**BIO-TECH LIMITED**  
 (AN ISO CERTIFIED COMPANY)  
 CIN LO1122GJ2004PLC043550



d.	Brief particulars of the management of the company	Jagdish Ajudia Maltiben Ajudia Priyanka Ajudia Mrs. Neha Patel Mrs. Shilpa Thumar Mrs. Ritaben Kikani Mrs. Rinku Jethva Ms. Dimpay Joshi All the Directors possess requisite knowledge in the industry.	Managing Director Whole Time Director Executive Director Non-Executive Independent Director Non-Executive Independent Director Independent Director Chief Finance Officer Company Secretary
e.	Names, addresses, DIN and occupations of the directors	<b>Annexure- A</b>	
f.	Management's perception of risk factors		
g.	Details of default, if any, including therein the amount involved, duration of default and present status, in repayment of –	NA	
	i) statutory dues;	NA	
	ii) debentures and interest thereon;	NA	
	iii) deposits and interest thereon;	NA	
	iv) loan from any bank or financial institution and interest thereon.	NA	





**INDO US**  
**BIO-TECH LIMITED**  
 (AN ISO CERTIFIED COMPANY)  
 CIN LO1122GJ2004PLC043550



h.	Names, designation, address and phone number, email ID of the nodal/ compliance officer of the company, if any, for the private placement offer process	Ms. Dimpy Joshi, Company secretary & compliance officer Address: 309, Shanti Mall, Satadhar Char Rasta Opp. Navrang Tower, Sola Road Ahmedabad 380061 Gujarat India Phone: 96389 94141 Mail: indouscs@gmail.com
----	---	---

## 2. PARTICULARS OF THE OFFER

a.	Date of passing of board resolution	08/07/2022
b.	Date of passing of resolution in the general meeting, authorizing the offer of securities	01/08/2022
c.	Kinds of securities offered (i.e. whether share or debenture) and class of security	Equity Shares
d.	Price at which the security is being offered including the premium, if any, along with justification of the price	INR 71/- (Face Value of INR 10/- and premium of INR 61/-)
e.	Name and address of the Valuer who performed valuation of the security offered	Mr. MANISH SANTOSH BUCHASIA (RV Registration No – IBBI/RV/03/2019/12235) Address: 306, "GALA MART" Nr SOBO CENTRE, SOUTH BOPAL, Ahmedabad -380058, Gujarat
f.	Amount which the company intends to raise by way of securities	Rs. 7,69,14,300/- (Including premium amount of Rs. 6,60,81,300)





**INDO US**  
**BIO-TECH LIMITED**  
 (AN ISO CERTIFIED COMPANY)  
 CIN LO1122GJ2004PLC043550



g.	Terms of raising of securities: Duration, if applicable, Rate of dividend or rate of interest, mode of payment and repayment	Equity shares being issued at Rs. 71/- having face value amount of Rs. 10 and premium of Rs. 61/- with other already issued equity shares; The consideration is made in cash as fully paid up.
h.	Proposed time schedule for which the offer letter is valid	One Month from date of issue
i.	Purposes and objects of the offer	The proceeds of the issue will be utilized for meeting long term fund requirements; and other general corporate purposes of the Company
j.	Contribution being made by the promoters or directors either as part of the offer or separately in furtherance of such objects	Yes
k.	Principle terms of assets charged as security, if applicable	NA - Allotment is made for cash





**INDO US**  
**BIO-TECH LIMITED**  
 (AN ISO CERTIFIED COMPANY)  
 CIN LO1122GJ2004PLC043550



### 3. DISCLOSURES WITH REGARD TO INTEREST OF DIRECTORS, LITIGATION ETC.

i.	Any financial or other material interest of the directors, promoters or key managerial personnel in the offer and the effect of such interest in so far as it is different from the interests of other persons.	The offer is being made to the promoters for 2,50,000 number of shares in the said allotment.
ii.	Details of any litigation or legal action pending or taken by any Ministry or Department of the Government or a statutory authority against any promoter of the offeree company during the last three years immediately preceding the year of the circulation of the offer letter and any direction issued by such Ministry or Department or statutory authority upon conclusion of such litigation or legal action shall be disclosed	NA
iii.	Remuneration of directors (during the current year and last three financial years);	





**INDO US**  
**BIO-TECH LIMITED**  
 (AN ISO CERTIFIED COMPANY)  
 CIN LO1122GJ2004PLC043550



iv.	Related party transactions entered during the last three financial years immediately preceding the year of circulation of offer letter including with regard to loans made or, guarantees given or securities provided	<b>Annexure-B</b>
v.	Summary of reservations or qualifications or adverse remarks of auditors in the last five financial years immediately preceding the year of circulation of offer letter and of their impact on the financial statements and financial position of the company and the corrective steps taken and proposed to be taken by the company for each of the said reservations or qualifications or adverse remark	<ul style="list-style-type: none"> <li>• The company has not maintained signed minutes for the F.Y. 2021-22.</li> <li>• The company has not maintained Registers and records required to be maintained under the Payment of Bonus Act, 1965.</li> <li>• The company has not placed the statement containing the names, their last known addresses and the unpaid dividend to be paid to each person on website of the company.</li> <li>• The company has not complied with the provisions of filing of Form BEN-2</li> <li>• The company has not maintained signed minutes for the FY 2020-21.</li> <li>• The company has not maintained Registers and records required to be maintained under The Payment of Bonus Act,1965</li> <li>• The Board of Directors of the Company/Committee(s) of Directors is not duly constituted with proper balance of Executive Directors, NonExecutive Directors and Independent Directors. There were some changes during the year in composition of Board.</li> <li>• The Company has not complied with The Payment of Gratuity Act, 1972 and rules and regulations, guidelines made there under. In financial statements (F.Y.2018-2019), the company has not provided Gratuity liability. No actuarial valuation report taken by the company from the Valuer in this regard.</li> </ul>







**INDO US**  
**BIO-TECH LIMITED**  
 (AN ISO CERTIFIED COMPANY)  
 CIN LO1122GJ2004PLC043550



vi.	Details of any inquiry, inspections or investigations initiated or conducted under the Companies Act or any previous company law in the last three years immediately preceding the year of circulation of offer letter in the case of company and all of its subsidiaries. Also if there were any prosecutions filed (whether pending or not) fines imposed, compounding of offences in the last three years immediately preceding the year of the offer letter and if so, section-wise details thereof for the company and all of its subsidiaries	NA
vii.	Details of acts of material frauds committed against the company in the last three years, if any, and if so, the action taken by the company	NA





**INDO US**  
**BIO-TECH LIMITED**  
 (AN ISO CERTIFIED COMPANY)  
 CIN LO1122GJ2004PLC043550



#### 4. FINANCIAL POSITION OF THE COMPANY

a) the capital structure of the company in the following manner in a tabular form

i.(a)	the authorized, issued, subscribed and paid up capital (number of securities, description and aggregate nominal value)	Authorised Capital: 10,00,000 equity shares of Rs. 10 each aggregating to INR 1,00,00,000 subscribed and paid-up capital: 91,66,700 equity shares of Rs. 10 each aggregating to INR 91,66,7,000/-
(b)	size of the present offer	10,83,300 shares of Rs. 71 each aggregating to INR 7,69,14,300
(c)	paid up capital	Current Paid up – INR 91,66,7,000/-
	(A) after the offer	After Allotment – 10,25,00,000
	(B) after conversion of convertible instruments (if applicable)	NA
(d)	share premium account (before and after the offer)	Before the offer - Rs. 14,60,22,918/- After the offer - NA- No Accounts closed till date
ii.	the details of the existing share capital of the issuer company in a tabular form, indicating therein with regard to each allotment, the date of allotment, the number of shares allotted, the face value of the shares allotted, the price and the form of consideration	<b>Annexure-C</b>







**INDO US**  
**BIO-TECH LIMITED**  
 (AN ISO CERTIFIED COMPANY)  
 CIN LO1122GJ2004PLC043550



Provided that the issuer company shall also disclose the number and price at which each of the allotments were made in the last one year preceding the date of the offer letter separately indicating the allotments made for considerations other than cash and the details of the consideration in each case;

b) Profits of the company, before and after making provision for tax, for the three financial years immediately preceding the date of circulation of offer letter –

Particulars	2021-22	2020-21	2019-20
Profit Before Tax	54897216	41268149	28637831
Profit After Tax	52372877	50979699	25347262

c) Dividends declared by the company in respect of the said three financial years; interest coverage ratio for last three years (Cash profit after tax plus interest paid/interest paid)

Particulars	2021-22	2020-21	2019-20
Dividend Declared	NA	2.5% (Interim dividend)	NA

d) A summary of the financial position of the company as in the three audited balance sheets immediately preceding the date of circulation of offer letter – Annexure- D

e) Audited Cash Flow Statement for the three years immediately preceding the date of circulation of offer letter – Annexure- E





**INDO US**  
**BIO-TECH LIMITED**  
(AN ISO CERTIFIED COMPANY)  
CIN LO1122GJ2004PLC043550



- f) Any change in accounting policies during the last three years and their effect on the profits and the reserves of the company – NA

5. A DECLARATION BY THE DIRECTORS THAT-

- a) the company has complied with the provisions of the Act and the rules made thereunder;
- b) the compliance with the Act and the rules does not imply that payment of dividend or interest or repayment of debentures, if applicable, is guaranteed by the Central Government;
- c) the monies received under the offer shall be used only for the purposes and objects indicated in the Offer letter;

I am authorized by the Board of Directors of the Company vide resolution dated July 8, 2022 to sign this form and declare that all the requirements of Companies Act, 2013 and the rules made thereunder in respect of the subject matter of this form and matters incidental thereto have been complied with. Whatever is stated in this form and in the attachments thereto is true, correct and complete and no information material to the subject matter of this form has been suppressed or concealed and is as per the original records maintained by the promoters subscribing to the Memorandum of Association and Articles of Association.





**INDO US**  
**BIO-TECH LIMITED**  
(AN ISO CERTIFIED COMPANY)  
CIN LO1122GJ2004PLC043550



It is further declared and verified that all the required attachments have been completely, correctly and legibly attached to this form.

**By the order of Board**  
**For INDO US BIO-TECH LIMITED**

**Sd/-**  
**JAGDISHKUMAR DEVJIBHAI AJUDIYA**  
**Director**  
**DIN: 01745951**

**Date: August 02, 2022**  
**Place: Ahmedabad**





**INDO US**  
**BIO-TECH LIMITED**  
 (AN ISO CERTIFIED COMPANY)  
 CIN LO1122GJ2004PLC043550



### Annexure-A

Name	Address	DIN	Occupation
JAGDISHKUMAR DEVJIBHAI AJUDIYA	B-201, DEV SHRUSTI APPARTMENT, SCIENCE CITY ROAD, SOLA, AHMEDABAD Gujarat, India 380015	01745951	Business
MALTI JAGDISHBHAI AJUDIA	B-201, DEV SHRUSTI APPARTMENT, SCIENCE CITY ROAD, SOLA, AHMEDABAD Gujarat, India 380015	02403878	Business
PRIYANKA JAGDISHBHAI AJUDIA	B-201, DEV SHRUSTI APPARTMENT, SCIENCE CITY ROAD, SOLA, AHMEDABAD Gujarat, India 380015	07941023	Business
RITABEN NILESHBHAI KIKANI	A-59, PRATIK TENAMENT, NR. INDIA COLONY, T.B. NAGAR, AHMADABAD, Gujarat India 382350	08367656	Business
SHILPA CHETANBHAI THUMAR	E-701 Aaryan Gloria Gala Gym Khana Road, Gala Gym Khana Road,South Bop Ahmedabad Gujarat India 380058	09259942	Business
NEHABEN SACHINBHAI PATEL	13, Green Wood Society, B/h J.G International School, Sola Road, Ahmedabad Gujarat India 380061	09263180	Business





**INDO US**  
**BIO-TECH LIMITED**  
(AN ISO CERTIFIED COMPANY)  
CIN LO1122GJ2004PLC043550



## Annexure-B

### Related party transactions entered during the last three financial years

Sr. No.	Name of the Related Party	Nature of Transaction
1.	Shree Patel Beej Nigam	Purchases and sale of goods
2.	Indo US Agriseeds private Limited	sale of goods
3.	Agri Pari E-Commerce Private Limited	sale of goods, Loan Granted, Investment in Subsidiary





**INDO US**  
**BIO-TECH LIMITED**  
 (AN ISO CERTIFIED COMPANY)  
 CIN LO1122GJ2004PLC043550



### Annexure-C

the details of the existing share capital of the issuer company in a tabular form, indicating therein with regard to each allotment, the date of allotment, the number of shares allotted, the face value of the shares allotted, the price and the form of consideration

Sr. no.	date of allotment	number of shares allotted	face value of the shares	price	form of consideration
1.	On incorporation	10000	10	100000	Cash
2.	31.03.2007	180000	10	1800000	Cash
3.	31.03.2008	35000	10	350000	Cash
4.	15.11.2008	120500	10	1205000	Cash
5.	18.03.2009	154500	10	1545000	Cash
6.	14.10.2009	250000	10	2500000	Cash
7.	31.03.2011	344366	10	3443660	Cash
8.	31.03.2012	94500	10	945000	Cash
9.	30.03.2015	300000	10	3000000	Cash
10.	04.12.2017	1935526	10	-	Bonus
11.	08.05.2018	1430000	10	72930000	Cash
12.	26.04.2019	1213598	10	-	Bonus
13.	07.12.2021	1213598	10	-	Bonus
14.	21.03.2022	416700	10	32115069	cash
15.	21.03.2022	1468412	10	113170512.84	Other than cash







**INDO US**  
**BIO-TECH LIMITED**  
 (AN ISO CERTIFIED COMPANY)  
 CIN LO1122GJ2004PLC043550



#### Annexure- D

**A summary of the financial position of the company as in the three audited balance sheets immediately preceding the date of circulation of offer letter**

Particulars	Year Ended on 31/03/2022	Year Ended on 31/03/2021	Year Ended on 31/03/2020
Income from operations	50,05,31,176.00	40,08,71,020.00	39,76,13,778.00
Other Income	18,27,332.00	4,29,876.00	78,526.00
Depreciation & amortization	42,28,987.00	25,04,437.00	21,36,182.00
Expenses other than Depreciation	6,25,78,681.00	8,80,78,840	3,37,66,760.00
Preliminary Exp. Written off	1,44,292.00	1,44,292.00	1,44,292.00
Net Profit/(Loss) Before Tax	5,48,97,216.00	4,12,68,149.00	2,86,37,831.00
Current Tax	37,89,756	-	22,07,800.00
Deferred Tax	(15,61,600.00)	(32,91,783.00)	7,82,539
Prior period Tax adjustment	0.00	0.00	0.00





**INDO US**  
**BIO-TECH LIMITED**  
 (AN ISO CERTIFIED COMPANY)  
 CIN LO1122GJ2004PLC043550



Profit/(Loss) After Tax	5,23,72,877.00	5,09,79,699.00	2,53,47,262.00
Proposed Dividend	15,16,998.00	0.00	0.00
Provision for dividend distribution Tax	0.00	0.00	0.00
Balance Carried to Balance Sheet	5,23,72,877.00	5,09,79,699.00	2,53,47,262.00



## Annexure- E

Audited Cash Flow Statement for the three years immediately preceding the date of circulation of offer letter

### Standalone Cash Flow Statement for the financial year ended on 31st March 2022

	Amount In 31-Mar-2022	Amount In 31-Mar-2021
<b>Cash flow from operating activities:</b>		
Net profit before tax as per statement of profit and loss	5,48,97,216	4,12,68,150
<b>Adjusted for:</b>		
Preliminary expenses	1,44,292	1,44,292
Provision /(Reversal) for gratuity	57,441	(1,85,007)
Depreciation & amortization	42,28,987	25,04,437
Loss on sale of asset or written off during the year	-	1,19,749
Interest income on loans & advances given	(25,635)	(16,721)
Interest & finance costs	1,17,57,931	1,16,49,921
<b>Operating cash flow before working capital changes</b>	<b>7,10,60,233</b>	<b>5,54,84,821</b>
<b>Adjusted for:</b>		
(Increase)/ decrease in inventories	(11,47,74,657)	(2,73,16,997)
(Increase)/ decrease in trade receivables	4,15,30,279	(3,71,74,675)
(Increase)/ decrease in other current assets	80,864	(23,741)
(Increase)/ decrease in non current advance and Other assets	46,03,173	(30,01,670)
Increase/ (decrease) in other non current liabilities	26,86,738	18,19,551
Increase/ (decrease) in trade payables	3,23,76,469	68,72,536
Increase/ (decrease) in other current liabilities	(46,13,061)	50,23,873
Increase/ (decrease) in long term provisions	-	-
Increase/ (decrease) in short term provisions	-	19,40,742
<b>Cash generated from / (used in) operations</b>	<b>3,29,50,037</b>	<b>36,24,440</b>
Income taxes paid	(38,68,222)	(13,76,267)
<b>Net cash generated from/ (used in) operating activities</b> [A]	<b>2,90,81,815</b>	<b>22,48,173</b>
<b>Cash flow from investing activities:</b>		
Purchase of fixed assets and Payment for CWIP	(3,96,66,166)	(1,90,75,655)
Sales of fixed assets	-	1,00,000
Purchase of equity shares	-	(99,000)
Increase/ decrease in short term loans and advances	(1,43,81,475)	15,13,722
Interest income on loans & advances given	25,635	16,721
<b>Net cash flow from/(used) in investing activities</b> [B]	<b>(5,40,22,006)</b>	<b>(1,75,44,212)</b>

**Cash flow from financing activities:**

Proceeds from issue of equity shares / Addition in Capital		<b>2,70,85,500</b>	-
Dividend Paid		<b>(15,16,998)</b>	
Proceeds from long term borrowing (net)		<b>3,70,277</b>	2,50,89,882
Proceeds from short term borrowing (net)		<b>99,23,944</b>	11,70,050
Interest & finance costs		<b>(1,17,57,931)</b>	(1,16,49,921)
<b>Net cash flow from/(used in) financing activities</b>	<b>[C]</b>	<b>2,41,04,793</b>	<b>1,46,10,011</b>
<b>Net increase/(decrease) in cash &amp; cash equivalents</b>	<b>[A+B+C]</b>	<b>(8,35,398)</b>	<b>(6,86,028)</b>
Cash & cash equivalents as at beginning of the year		<b>13,18,302</b>	<b>20,04,330</b>
<b>Cash &amp; cash equivalents as at end of the year [Refer Note No.18]</b>		<b>4,82,904</b>	<b>13,18,302</b>

**Notes:**

1. The above Cash Flow Statement has been prepared under "Indirect Method" set out in Accounting Standard - 3 on "Cash Flow Statements".
2. Figures in brackets indicate cash outgo.
3. Previous year's figures have been regrouped/ rearranged wherever necessary.

## Cash Flow Statement for the financial year ended on 31st March 2021

	Amount In Rs. 31-Mar-2021	Amount In Rs. 31-Mar-2020
<b>Cash flow from operating activities:</b>		
Net profit before tax as per statement of profit and loss	4,12,68,149	2,86,37,829
<b>Adjusted for:</b>		
Preliminary expenses	1,44,292	1,44,292
Provision /(Reversal) for gratuity	(1,85,007)	1,81,970
Depreciation & amortization	25,04,437	21,36,182
Loss on sale of asset or written off during the year	1,19,749	54,229
Interest income on loans & advances given	(16,721)	(300)
Interest & finance costs	1,16,49,921	84,62,122
<b>Operating cash flow before working capital changes</b>	<b>5,54,84,821</b>	<b>3,96,16,324</b>
<b>Adjusted for:</b>		
(Increase)/ decrease in inventories	(2,73,16,997)	1,56,52,569
(Increase)/ decrease in trade receivables	(3,71,74,675)	(11,91,62,364)
(Increase)/ decrease in other current assets	(23,741)	(1,03,885)
(Increase)/ decrease in other non-current assets	(30,01,670)	(2,00,000)
Increase/ (decrease) in other non-current liabilities	18,19,551	1,09,483
Increase/ (decrease) in trade payables	68,72,536	5,87,15,499
Increase/ (decrease) in other current liabilities	50,23,873	15,68,744
Increase/ (decrease) in long term provisions	-	1,67,011
Increase/ (decrease) in short term provisions	19,40,742	(44,94,511)
<b>Cash generated from / (used in) operations</b>	<b>36,24,441</b>	<b>(81,31,130)</b>
Income taxes paid	(13,76,267)	(3,00,230)
<b>Net cash generated from/ (used in) operating activities</b> [A]	<b>22,48,174</b>	<b>(84,31,360)</b>
<b>Cash flow from investing activities:</b>		
Purchase of fixed assets	(1,90,75,655)	(39,61,861)
Sales of fixed assets	1,00,000	3,39,000
Purchase of equity shares	(99,000)	-
Increase/ decrease in short term loans and advances	15,13,722	(20,46,531)
Interest income on loans & advances given	16,721	300
<b>Net cash flow from/(used) in investing activities</b> [B]	<b>(1,75,44,212)</b>	<b>(56,69,092)</b>
<b>Cash flow from financing activities:</b>		
Proceeds from issue of equity shares / Addition in Capital	-	-
Proceeds from long term borrowing (net)	2,50,89,882	(16,87,218)
Proceeds from short term borrowing (net)	11,70,050	2,54,32,600
Interest & finance costs	(1,16,49,920)	(84,62,122)
<b>Net cash flow from/(used in) financing activities</b> [C]	<b>1,46,10,011</b>	<b>1,52,83,260</b>
<b>Net increase/(decrease) in cash &amp; cash equivalents</b> [A+B+C]	<b>(6,86,027)</b>	<b>11,82,808</b>
Cash & cash equivalents as at beginning of the year	20,04,329	8,21,521
<b>Cash &amp; cash equivalents as at end of the year</b>	<b>13,18,302</b>	<b>20,04,329</b>

**Notes:**

1. The above Cash Flow Statement has been prepared under "Indirect Method" set out in Accounting Standard - 3 on "Cash Flow Statements".
2. Figures in brackets indicate cash outgo.
3. Previous year's figures have been regrouped/ rearranged wherever necessary.



## Cash Flow Statement for the Year ended on 31<sup>st</sup> March, 2020

	Amount In Rs. 2019- 2020	Amount In Rs. 2018-2019
<b>Cash flow from operating activities:</b>		
Net profit before tax as per statement of profit and loss	28,637,831	28,106,184
<b>Adjusted for:</b>		
Preliminary expenses	144,292	144,292
Provision for gratuity	181,970	357,248
Depreciation & amortization	2,136,182	2,401,654
Transferred to Adjustments in Reserves and Surplus	-	(2)
Asset written off during the year	54,229	129,664
Interest income on loans & advances given	(300)	(16,118)
Interest & finance costs	8,838,723	3,956,410
<b>Operating cash flow before working capital changes</b>	<b>39,992,927</b>	<b>35,079,332</b>
<b>Adjusted for:</b>		
(Increase)/ decrease in inventories	15,652,569	(45,114,533)
(Increase)/ decrease in trade receivables	(119,162,364)	(753,969)
(Increase)/ decrease in other current assets	(103,885)	(1,298,361)
(Increase)/ decrease in other non current assets	-	
Increase/ (decrease) in other non current liabilities	109,483	1,781,000
Increase/ (decrease) in trade payables	58,715,499	(24,524,035)
Increase/ (decrease) in other current liabilities	1,568,744	7,132,883
Increase/ (decrease) in long term provisions	167,011	
Increase/ (decrease) in short term provisions	(4,494,511)	(3,975,211)
<b>Cash generated from / (used in) operations</b>	<b>(7,554,527)</b>	<b>(31,672,894)</b>
Income taxes paid	(300,230)	(16,946)
<b>Net cash generated from/ (used in) operating activities</b>	<b>[A] (7,854,757)</b>	<b>(31,689,840)</b>
<b>Cash flow from investing activities:</b>		
Purchase of fixed assets	(3,961,861)	(12,930,472)
Sales of fixed assets	338,999	
Increase/ decrease in short term loans and advances	(2,046,531)	(12,214,294)
Increase/ decrease in long term loans and advances	(200,000)	(432,541)
Interest income on loans & advances given	300	16,118
<b>Net cash flow from/(used) in investing activities</b>	<b>[B] (5,869,093)</b>	<b>(25,561,189)</b>
<b>Cash flow from financing activities:</b>		
Proceeds from issue of equity shares / Addition in Capital	-	68,777,738
Proceeds from long term borrowing (net)	(1,687,218)	(7,102,939)
Proceeds from short term borrowing (net)	25,432,599	(356,142)
Interest & finance costs	(8,838,723)	(3,956,410)
<b>Net cash flow from/(used in) financing activities</b>	<b>[C] 14,906,658</b>	<b>57,362,247</b>
<b>Net increase/(decrease) in cash &amp; cash equivalents</b>	<b>[A+B+C] 1,182,808</b>	<b>111,218</b>
Cash & cash equivalents as at beginning of the year	821,521	710,303
<b>Cash &amp; cash equivalents as at end of the year</b>	<b>2,004,329</b>	<b>821,521</b>